Spyre Therapeutics (SYRE) Other Accumulated Expenses (2015 - 2026)

Spyre Therapeutics has reported Other Accumulated Expenses for 12 years, with the latest figure at $165000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 55.53% year-over-year to $165000.0; the trailing twelve-month figure through Mar 2026 stood at $165000.0 (down 55.53% YoY), and the FY2025 full-year result was $179000.0, down 64.27% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $165000.0, down from $179000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $726000.0 in Q1 2022, with the low at $165000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $361400.0 across 5 years, with a median of $362000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 97.82% — and 2025, when it tumbled 67.68%.
• Spyre Therapeutics' Other Accumulated Expenses stood at $330000.0 in 2022, then jumped by 47.88% to $488000.0 in 2023, then increased by 2.66% to $501000.0 in 2024, then slumped by 64.27% to $179000.0 in 2025, then declined by 7.82% to $165000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $165000.0 (Q1 2026), $179000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.